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Summary
As COVID–19 disease escalates globally, optimising patient outcome during this catastrophic healthcare crisis
is the number one priority. The principles of patient bloodmanagement are fundamental strategies to improve
patient outcomes and should be given high priority in this crisis situation. The aim of this expert review is to
provide clinicians and healthcare authorities with information regarding how to apply established principles of
patient blood management during the COVID–19 pandemic. In particular, this review considers the impact of
the COVID–19 pandemic on blood supply and specifies important aspects of donor management. We discuss
how preventative and control measures implemented during the COVID–19 crisis could affect the prevalence of
anaemia, and highlight issues regarding the diagnosis and treatment of anaemia in patients requiring elective
or emergency surgery. In addition, we review aspects related to patient blood management of critically ill
patients with known or suspected COVID–19, and discuss important alterations of the coagulation system in
patients hospitalised due to COVID–19. Finally, we address special considerations pertaining to supply-
demand and cost-benefit issues of patient bloodmanagement during theCOVID–19 pandemic.
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Introduction
In December 2019, the first reports of patients with
coronavirus disease 2019 (COVID-19) emerged, a disease
caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) [1]. Over the course of a few months,
COVID-19 has spread globally, with more than 2.8 million
confirmed cases at the time of writing [2]. This prompted the
World Health Organization (WHO) to declare the COVID-19
outbreak a pandemic [3]. During times of crisis, clinicians
are constantly being pushed to their limits. As numbers of
patients with COVID-19 are continuing to increase, new
scientific findings need to be integrated into routine clinical
practice. However, established evidence-based medical
concepts should still be followedwhen treating patients.
Patient blood management is a multimodal,
multidisciplinary approach based on timely application of a
bundle of evidence-based medical and surgical concepts
aimed at improving the outcome of patients at risk [4]. The
three pillars of patient blood management encompass
measures to optimise the patient’s red cell mass, reduce
peri-operative blood loss and enhance anaemia tolerance
[5]. In addition, patient bloodmanagement implementation
results in reduced transfusion rates and lower healthcare
costs [6, 7]. These aspects are crucial for national medical
systems during times when resources and funding are
limited. The aim of this expert review is to provide clinicians
and healthcare authorities with information on how to apply
the principles of patient blood management during the
COVID-19 pandemic.
Methods
This article is a focused expert review. The authors used
PubMed, Scopus and Web of Science for their literature
search. No standardised protocol for the literature search
was defined.
Impact onblood supply
In most countries around the world, COVID-19 has
generated an unprecedented healthcare and socio-
economic emergency. As a consequence of social
restrictions made by governments to fight the spread of
COVID–19, the number of blood donations has significantly
decreased during the last few weeks. In addition, although
to our knowledge there has been no scientifically
documented evidence yet of the transmission of COVID–
19 infection through transfusion of blood components,
the current outbreak has produced a heated debate
regarding the safety of blood donations in endemic
countries [8].
Following the indications from the European Centre
for Disease Prevention and Control regarding the supply
of substances of human origin [9], most European
National Health Competent Authorities have issued some
recommendations on the prevention of transmission of
COVID–19 infection through transfusion of labile blood
components. Beside the recommendation of employing
the hospitals’ patient blood management-based
programmes of blood saving, several actions have been
implemented in the setting of blood donor selection.
Specific donormanagement
The Italian National Blood Centre (Centro Nazionale
Sangue, CNS), the Health Ministry’s technical and scientific
advisory body on matters related to blood and blood
products, has issued a number of measures aimed at
maintaining high standards of blood donation and blood
safety in Italy, one of the countries with a higher incidence of
COVID-19-related casualties worldwide [10]:
1 Strengthen surveillance measures of individuals in
contact with subjects with documentedCOVID–19;
2 Defer blood donations from donors returning from any
national or international territory with a travel health
notice for 14 days, donors who have possibly been
exposed to the risk of infection by contact with subjects
with COVID–19 documented infection, and donors with
a history of COVID–19 infection (documented infection
or onset of symptoms compatible with COVID–19
infection) who are convalescent;
3 Require donors to inform their blood collection centres
in case of symptoms compatible with COVID–19
infection or in the case of diagnosis of COVID–19
infection within 14 days after donation (post-donation
information);
4 Promote the implementation of simple triage processes
during the reception of donors at blood collection units,
aiming to avoid the possible spread of the virus in
waiting rooms. This includes the measurement of body
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temperature outside the collection area. A body
temperature of 37.5°C or higher is defined as a criterion
for the temporary deferral of the donor;
5 Request all personnel working at blood collection units
to comply scrupulously with behavioural protocols
designed to prevent the spread of respiratory infections,
includingCOVID–19 infection.
Additional actions directed towards the management
of voluntary blood donors to ensure continuous and safe
donation of blood components include a timely appeal to
donate blood when shortage is foreseeable; careful
planning of the donor schedule to avoid an excessive
number of donors at blood collection centres as well as
compliance with social distancing measures; use of
adequate personal protective equipment; and meticulous
adherence to hygiene regulations. In addition, travel to
donate blood should be considered as essential by
governments or – if deemed non-essential – provision of
a certificate allowing travel to the collection centre should
be provided. The application of these recommendations
has facilitated the safer management of blood donations
and, following an initial 10% decrease in whole blood
collection, has maintained a stable volume of total blood
donations (approximately 50,000 units per week), thus
guaranteeing blood component self-sufficiency and safety
in Italy.
Anaemia
In major elective surgery, patients can be exposed to the
effects of pre-operative anaemia, blood loss and red cell
transfusion, all of which adversely influence postoperative
outcome [11, 12]. In patients undergoing major surgical
procedures, it is recommended that pre-operative anaemia
be defined by haemoglobin < 130 g.l1, irrespective of sex
[13, 14]. Using this definition, in a large cohort of major
elective procedures, the overall prevalence of pre-operative
anaemia was 36%. Over 70% of anaemic patients presented
with absolute or functional iron deficiency, resulting in iron-
restricted erythropoiesis [15]. In addition, pre-operative iron
deficiency in patients undergoing cardiac surgery is
associated with a three-fold increased 90-day mortality [16].
Non-anaemic haematinic deficiencies are also prevalent
and may hamper pre-operative haemoglobin optimisation
and/or recovery from postoperative anaemia [5, 15]. As for
non-elective procedures, up to 75% of patients undergoing
hip fracture repair surgery presented with haemoglobin
< 130 g.l1on admission [17].
These figures could be expected to increase during the
COVID-19 pandemic due to changes in diet and lifestyle,
aggravated by a reduced purchasing power and decreased
incomes. Possible consequences include: a reduced
consumption of fresh food, including fruit and vegetables
(vitamin C, folic acid), dairy products (vitamin D), fish and
meat (iron, vitamin B6, vitamin B12); and a lack of sunlight
exposure and muscle atrophy resulting from curfew
restrictions and social distancing. Consequently,
proliferation of red cell progenitors, iron homeostasis and
haemoglobin synthesis, as well as overall physical and
mental performance, could be affected [18, 19]. Depending
on their general health condition and the duration of the
COVID-19 pandemic, the elderly are likely to be the most
affected [20]. Most importantly, this population has the
greatest comorbidity load and represents the largest
proportion of hospitalisedmedical and surgical patients.
Diagnosis and treatment of anaemia in
patients awaiting elective surgery
During the COVID-19 pandemic, elective medical activity is
markedly reduced and elective surgery is frequently
postponed, with priority given to urgent and emergency
surgery. Pre-operative anaemia clinics, which function to
screen, diagnose, and treat iron deficiency and other causes
of anaemia are mostly closed and appointments cancelled.
As a result, blood testing and diagnostic tools are less
readily available, hampering the diagnosis and treatment of
anaemia of various causes. Remote (telephone or video)
consultations are possible and have become much more
widespread. It is certainly possible to elicit the most
common symptoms of severe iron deficiency: fatigue/
exhaustion; brain fog; palpitations, shortness of breath;
anxiety; low mood/depression; aching and restless legs;
alopecia, brittle/ridged fingernails; and pica (appetite for
non-nutritive substances). Patients with these symptoms
should be expedited to iron therapy. Iron deficiency
anaemia may worsen over time, so early treatment is
favoured. Intravenous (i.v.) iron administration is preferred,
either via anaemia clinics or through general practitioners as
it yields rapid results. However, as administering i.v. iron
might not be feasible during the pandemic, oral ironmay be
the treatment of choice to correct iron deficiency and treat
anaemia when non-urgent surgery is delayed and waiting
periods are prolonged. Alternate-day treatment with oral
iron is recommended, rather than daily doses, to improve
uptake and compliance [21]. Newer oral iron formulations
with enhanced absorption and gastro-intestinal tolerability,
such as sucrosomial iron, should be considered [22]. This
line of action is also practicable in individuals who cannot
leave their home due to quarantinemeasures. Once surgery
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is rescheduled, diagnostic testing for haemoglobin, ferritin,
C-reactive protein (CRP), and transferrin saturation should
be undertaken during pre-operative assessment.
Diagnosis and treatment of anaemia in
patients admitted for emergency
surgery
As stated above, the incidence and severity of anaemia is
likely to increase during the pandemic due to changes in
diet and lifestyle. Thus, we may experience a greater
proportion of patients admitted for urgent or emergency
surgery being anaemic. Low ferritin (< 30 ng.ml1) is often
used as an indicator of very low iron stores and iron
deficiency. However, ferritin is increased during acute
phase inflammation as may be seen with viral infections
such as COVID–19. Consequently, the use of ferritin to
diagnose iron deficiency may be problematic in patients
with COVID-19 disease, who may have normal or high
ferritin levels despite very low iron stores [23]. Hence, we
recommend concurrent measurement of CRP and
transferrin saturations. Transferrin saturation < 20% strongly
suggests iron deficiency, especially when ferritin is
< 100 ng.l1 [13]. Increased CRP (> 4 mg.l1) indicates that
ferritin measurement alone is unreliable due to acute
inflammation or viraemia. The bone marrow response to i.v.
iron starts early after infusion, with a peak haemoglobin
concentration within the following 4–6 weeks [24]. If urgent
surgery is necessary in patients with iron deficiency
anaemia, i.v. iron should be favoured over oral iron [13]. The
benefit of short-term treatment with i.v. iron has been
demonstrated in patients undergoing orthopaedic [25] and
cancer surgery [26–28]. In addition, administering high-
dose i.v. iron pre-operatively, even on the day of surgery,
could help prevent postoperative anaemia [29]. This
approach is also feasible in iron-deficient COVID-19
patients admitted for urgent procedures. In patients with
more profound anaemia, an ultra-short-term treatment
course (1–2 days before surgery) of erythropoietin and i.v.
iron may bemore effective. A regimen of 40,000 IU epoetin
alpha and 1000 mg i.v. iron, together with 1 mg
subcutaneous vitamin B12 and 5 mg oral folic acid, has
been shown to reduce blood transfusion in cardiac surgery
patients [30]. The beneficial effects of very short-term
treatment with i.v. iron and epoetin alpha have also been
observed in elective and non-elective orthopaedic surgery
[25]. Intravenous iron is also effective for treating
postoperative anaemia, and should be considered, even in
cancer patients who are undergoing surgery during the
COVID-19 crisis [26, 31, 32].
Patient bloodmanagement in critically
ill patientswith knownor suspected
COVID-19
Early reports have described mild anaemia in COVID-19
patients admitted to the ICU [33, 34]. In general, the most
common aetiologies for anaemia in the ICU are
inflammation and iron deficiency. Just as in surgical
patients, iron, vitamin B12, folic acid and erythropoietin can
be administered in critically ill patients [35]. Intravenous iron
formulations are superior to oral formulations in such
patients, as enteral iron uptake is reduced in inflammatory
states due to increased expression of hepcidin. Moreover, a
recent meta-analysis suggested that therapy with
erythropoietin may decrease mortality in critically ill adults,
even though results were described as hypothesis-
generating by the authors [36]. In COVID-19 positive
critically ill patients, the risk of thrombosis associated with
erythropoiesis-stimulating agents has to be individually
considered before each administration, and mitigated with
anticoagulation. When a shortage of blood supply is
anticipated, treatment should be initiated early, before
anaemia reaches critical levels. To balance the risks,
haemoglobin should be maintained at levels sufficient to
enable adequate oxygenation. This process can be
achieved with below-normal haemoglobin values in most
patients. In addition, patients should be anticoagulated
adequately whenever possible, and special consideration
given to the possible prothrombotic nature of COVID-19 in
critically ill patients [37]. Prevention of anaemia is just as
important as treatment of anaemia in critically ill patients.
Anaemia is aggravated by repeated blood tests in non-
bleeding critically ill patients, especially those with acute
respiratory distress syndrome (ARDS) or sepsis [38]. Blood
sampling is increased in severely affected patients due to
frequent blood gas analyses, laboratory testing, and blood
culture testing. Two simple ways to prevent iatrogenic
blood loss are micro-sampling and the use of blood
conservation devices to reduce the amount of discarded
blood [39]. For each blood test, the lowest possible amount
of blood necessary to perform testing should be drawn, and
only tests that are essential for clinical decisions should be
ordered.
Acute respiratory distress syndrome is common in
COVID-19 patients who develop pneumonia [34, 40].
Transfusion of red cells has been associated with negative
clinical effects on the lung, such as transfusion-related
acute lung injury or pulmonary hypertension [41]. These
side-effects might enhance the severity of ARDS in
affected patients [42]. Thus, it is important to carefully
1108 © 2020 TheAuthors.Anaesthesia published by JohnWiley & Sons Ltd on behalf of Association of Anaesthetists
Anaesthesia 2020, 75, 1105–1113 Baron et al. | Patient bloodmanagement during theCOVID-19 pandemic
consider each indication for transfusion, taking into
account individual factors such as age, intravascular
volume status of the patient and concomitant diseases.
Before transfusing allogeneic red cells, measures that
increase oxygen delivery should be utilised, including
improvement of oxygen saturation and cardiac output.
Total erythrocyte mass is not always reflected by
haemoglobin values and it is not advisable to merely focus
on transfusion thresholds. Whenever possible, a single-unit
policy should be followed in order to limit volume
transfused and multiple donor exposure, except in
patients with active massive bleeding.
Alterations of coagulation in COVID-19
patients
Several reports describe coagulation alterations in patients
hospitalised with COVID-19 infection [40, 43–45]. In these
reports, prothrombin time and activated partial
thromboplastin time were longer in COVID-19-infected vs.
non-infected individuals. In addition, more abnormal
coagulation parameters were found in advanced disease
states and in non-survivors compared with survivors [40, 44,
45], together with elevated fibrinogen concentrations [43,
44]. Markedly elevated D-dimers were described as the
most prominent characteristic, a finding interpreted as overt
disseminated intravascular coagulation (DIC) [44]. A sub-set
of patients with the most severe COVID-19 are prone to
develop consumptive coagulopathy and a hypercoagulable
state. Furthermore, the most severely affected COVID-19
patients may require extracorporeal membrane
oxygenation (ECMO) for respiratory (or cardiac) failure. This
treatment can be life-saving, but also transfusion-intensive
with anecdotal reports of frequent clotting within the ECMO
circuits. As new insights are gained about the
pathophysiology of these prothrombotic alterations in
COVID-19 patients, it will be important to adapt therapy
accordingly [46]. Early prehospital low-dose aspirin or early
in-hospital low molecular weight heparin have been
proposed as pre-emptive treatment strategies. However,
premature and unsubstantiated changes in therapeutic
concepts should be avoided when based merely on
anecdotal reports, as the consequences may be
deleterious. Patients should be enrolled in ethically
approved trials, and the results of these ongoing
randomised trials should guide future therapeutic advances
in treatment.
To our knowledge, there is no study yet published in
which thrombo-elastographic or thrombo-elastometric
techniques are used to assess coagulation in COVID-19
infected patients. Monitoring coagulation with viscoelastic
point-of-care devices and quick laboratory tests is crucial in
all bleeding patients and is recommended by the European
Society of Anaesthesiology [47], the European Association
for Cardiothoracic Surgery, the European Association of
Cardiothoracic Anesthesiology [48], and by the European
Guidelines on management of major bleeding and
coagulopathy following trauma [49]. Such timely
coagulation monitoring allows rapid detection of
disturbances in the coagulation system, and to accurately
diagnose the abnormality. On this basis, an individualised
goal-directed coagulation treatment using coagulation
factors according to an algorithm is possible. The success of
such treatment algorithms has been shown in cardiac
surgery [50], trauma [51], and major postpartum
haemorrhage [52]. Of particular relevance during the
current COVID-19 pandemic is that the use of treatment
algorithms can reduce transfusions of red cells, plasma, and
platelets as well as admission to ICU, and shorten ventilation
time and ICU length of stay [50–52]. A simple and pragmatic
coagulation algorithm is depicted in Fig. 1. The success of
viscoelastic point-of-care based algorithms is largely
independent of the use of thrombo-elastographic or
thrombo-elastometric techniques [53]. In addition, in a
recent study, the latest models of both types of viscoelastic
techniqueswere found to be largely comparable [54].
Irrespective of the type of coagulation algorithm used,
the early use of tranexamic acid may be recommended to
manage the bleeding patient provided there is no
contraindication (active DIC or active hypercoagulable state
being absolute contraindications) [55]. At present, there are
close to 200 meta-analyses that show the success of
tranexamic acid in reducing bleeding and the use of
allogeneic blood products in surgery and in non-surgical
fields. These meta-analyses also document the absence of
an increased incidence of thromboembolic adverse
outcomes following tranexamic acid administration [4].
Some COVID-19 infected patients need surgery during
their ICU stay. In an early phase, most patients are likely to
be in a distinct acute phase response with very high levels of
platelets, fibrinogen concentration, Factor VIII and von
Willebrand factor. Later, some may develop DIC. However,
the current level of knowledge is very limited and the
difference between patients at different stages of the
disease is likely to be significant. Therefore, monitoring
coagulation with viscoelastic point-of-care devices and
quick laboratory tests is particularly important in COVID-19
infected patients. At the present time we propose using the
established coagulation algorithms (Fig. 1) including the
use of tranexamic acid in COVID-19 positive patients with
less severe disease suffering from trauma.
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Special considerations
During disasters, work forces are overstrained, supply
chains are disrupted, manufacturing capacities are reduced
or diverted, and infrastructures are undermined in the face
of increased demand. These circumstances lead to
shortages of crucial medical resources. This reality is
exemplified during the COVID-19 pandemic by the
shortage of personal protective equipment, ventilators, ICU
beds, vital medications and other critical equipment for
healthcare workers and frontline responders. All this puts
medical personnel at great personal risk and forces difficult
decisions to be made regarding the allocation of scarce
patient resources [56]. Considering the many uncertainties
of the COVID-19 pandemic, the full extent of consequences
remains unknown. Some models suggest a direct human
toll in the tens of thousands in US alone, extrapolating to
hundreds of thousands of deaths globally. Indirectly, as
economies around the world suffer, populations face risks
due to disrupted healthcare systems, reduced access to
care and preventative measures, impaired mental health
and poverty. There is often a sinister inverse relationship
between measures of economic prosperity and various
health and well-being indicators [57]. Patient blood
management can play an important role in mitigating short-
term shortages in the midst of the acute phase of the
pandemic (and subsequent waves until herd immunity is
established through widespread infection or vaccination)
and longer-term socio-economic health challenges in the
post-COVID-19 world. The main focus of patient blood
management on improving patients’ outcomes can directly
translate into a reduced burden of illness and severity in
individual patients, releasing limited resources for other
Figure 1 Individualised goal-directed coagulation and transfusion algorithm in the case of blood loss ≥ 50%or diffuse
bleeding (adapted froman algorithmof the Institute of Anaesthesiology, University Hospital Zurich, Switzerland). ACT, activated
clotting time; COVID-19, coronavirus disease 2019; CFT, clot formation time; CT, clotting time; DIC, disseminated intravascular
coagulation; INR, international normalised ratio; IU, international units;MAP,mean arterial pressure;MCF,maximumclot
firmness; PCC, prothrombin complex concentrate; PT, prothrombin time; ROTEM, rotational thrombo-elastometry; TBI,
traumatic brain injury; TT, thrombin time.
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needs. Patient blood management practices prevent
anaemia (a global health problem) and reduce allogeneic
blood transfusion, resulting not only in the best allocation of
resources and cost savings, but also decreased patient
morbidity and mortality [6, 58]. These improved outcomes
and the concomitant cost savings are urgently needed as
we deal with a pandemic yet to reach its peak, and the
ongoing challenges thereafter.
During the COVID-19 pandemic, themost fundamental
aspect of patient blood management is the prevention and
management of anaemia. While the exact impact of
anaemia on the outcomes of COVID-19 patients is not yet
fully understood, data show unequivocally that the
prognosis of COVID-19 patients with pre-existing and
chronic conditions is significantly worse. As such, it is not
unreasonable to expect that anaemia will also have a
negative impact on the outcomes of COVID-19 patients and
widespread prevention andmanagement of anaemiamight
confer some protection against more severe cases of
COVID-19.
Conclusion
As we are facing the biggest global health challenge of our
lives, only a major collaborative effort will allow us to
achieve a positive outcome. Using a patient-centred
approach, proven evidence-based principles should be
applied and established expert-consensus good practice
concepts continued. Patient blood management is one
piece of the puzzle needed to save patients’ lives. Every
drop of blood saved can be decisive, even more so in the
critical situationwe are currently facing.
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